906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL)

Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP)

Effect of prior CD19 directed monoclonal antibody exposure on outcomes in patients subsequently treated with CD19 targeting CAR T therapy A multicenter propensity score matched retrospective cohort study

Automated classification of acute lymphoblastic leukemia in peripheral blood smears using a convoluted neural network ResNet18 model

Reduction of infections with intravenous immunoglobulin in chronic lymphocytic leukemia A single center retrospective analysis

Long term risk and racial disparities in second primary malignancies among diffuse large B cell lymphoma survivors A SEER based analysis MP SIR analysis 2000–2022

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T cell infusion in aggressive B cell lymphomas

Incidence of cardiac toxicities in patients with hematologic malignancies treated with zanubrutinib compared to control including BTK inhibitor Ibrutinib A meta analysis of randomized controlled trials

Number needed to treat to avoid progression or death Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed Refractory chronic lymphocytic leukemia

Incidence of second primary malignancies in patients with hematologic malignancies treated with next generation bruton tyrosine kinase BTK inhibitors A meta analysis of randomized controlled trials

Outcomes of patients with Relapsed Refractory aggressive B cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy

Outcomes and treatment strategies following CD20 CD3 bispecific antibody failure in non Hodgkin s lymphoma A retrospective single center study

Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B cell lymphoma

Anti CD3 CD20 bispecific antibodies as salvage therapy after CAR T failure in Relapsed Refractory large B cell lymphoma A systematic review and meta analysis

Patient reported outcomes and quality of life over time in relapsed refractory diffuse B cell lymphoma DLBCL patients treated with CAR T cells therapy in clinical practice

Chimeric antigen receptor T cell therapy in patients with coexisting malignancy and autoimmune disease

Cardiotoxicity profile of novel bispecific T cell engager therapies

Real world data of lisocabtagene maraleucel as second line therapy for patients with large B cell lymphoma Updated Results of the french descar T registry by lysa

Clinical outcomes of first line venetoclax based regimens vs second generation BTK inhibitors in CLL SLL A retrospective cohort study

Real world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T cell lymphomas A Florida multi institutional cohort study

Suboptimal cancer screening adherence in CLL SLL patients

Nationwide impact of CAR T approval on acute lymphoblastic leukemia mortality in the United States 1999 2023 Difference in differences and synthetic control analyses

Evaluation of outcomes by line of therapy in marginal zone lymphoma Real world evidence from 10 US academic centers

Real world comparative outcomes of CAR T cell therapy versus bispecific antibodies in patients with diffuse large B cell lymphoma

Optimizing high dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia

Treatment patterns and outcomes among patients treated with second generation BTK inhibitors in CLL

Impact of angiotensin converting enzyme inhibitors ACEis and angiotensin receptor blockers ARB on tumor lysis syndrome acute kidney injury and rasburicase use in patients undergoing chemotherapy for hematologic malignancies

Incidence of severe chemotherapy associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti emetic prophylaxis

Disparate post relapse survival outcomes by race ethnicity for children with B cell acute lymphoblastic leukemia An analysis from the recall 1 study

Rehabilitation needs and clinical associations post CAR T cell therapy A retrospective analysis

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T cell lymphoma PTCL A multicenter retrospective Study

Causes of death in chronic lymphocytic leukemia small lymphocytic lymphoma during the novel agent era A population based analysis

Impact of preexisting mental health disorders and psychiatric pharmacotherapy on hospital length of stay in immune effector cell therapy recipients

The impact of distance to CAR T centre on CAR T delivery and CAR T outcomes A single centre retrospective cohort study

Age stratified prognostic performance of patient vs disease related IPI factors in large B cell lymphoma

Real world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Evaluation of outcomes and toxicities of loncastuximab tesirine Lonca in relapse refractory R R diffuse large B cell lymphoma DLBCL and follicular lymphoma FL Real world data analysis RWDA from 10 US academic centers

Real world selection of fixed duration versus continuous therapies for treatment naïve chronic lymphocytic leukemia small lymphocytic lymphoma

Race ethnicity reporting and representation in clinical trials presented at plenary and late breaking abstract sessions at the American society of hematology ASH from 2014 to 2024

Analysis of real world overall survival rwOS among patients with third line or later 3L diffuse large B cell lymphoma DLBCL with multiple qualifying index dates treated in the United States

Estimating the survival impact of not receiving CAR T cell CAR T therapy when eligible in patients with relapsed or refractory R R diffuse large B cell lymphoma DLBCL in the United States US

Effectiveness of comprehensive geriatric assessment CGA in older patients with diffuse large B cell lymphoma DLBCL and the impact of frailty in treatment tolerability and survival in a prospective multicenter study

The impact of marginalization on outcomes in patients with Hodgkin lymphoma

Real world incidence of treatment emergent cardiovascular events among chronic lymphocytic leukemia small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Real world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first line CLL patients

Real world safety and mortality outcomes of CAR T cell therapies versus bispecific antibodies in DLBCL Insights from the faers database

Real world treatment patterns and survival outcomes in second and third line settings in large B cell lymphoma LBCL

Bispecific antibody vs non bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T cell CART failure in large B cell lymphoma

Clinical characteristics treatment patterns clinical outcomes and resource utilization in patients with chronic lymphocytic leukaemia CLL CREEK Latin America subgroup analysis

Respiratory viral infections are a significant cause of morbidity during long term follow up after CAR T cell therapy Analysis of 445 episodes

Risk of cardiovascular disease related mortality in hematologic malignancy patients A population level US retrospective cohort study 1975 2022

Center effect on large B cell lymphoma outcome in frontline prospective Phase II and III trials A lysa study

Unequal outcomes The role of institutional setting in the management of primary CNS lymphoma

Cyclophosphamide versus methotrexate for treating large granular lymphocyte leukemia Real world data insights

Risk of mental health outcomes and peak risk periods post hematologic cancer diagnosis in the United States

Real world insights into diffuse large B cell lymphoma from EHR derived data in Germany and the United Kingdom

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Real world measurable residual disease MRD testing patterns and associated outcomes in patients with Philadelphia negative B cell acute lymphoblastic leukemia

Real world survival cognitive and health related quality of life outcomes of methotrexate ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma

Real world treatment patterns and clinical outcomes in high risk Mantle Cell Lymphoma A retrospective analysis

Underreporting of prognostic factors in real world studies for bispecifics in relapsed or refractory diffuse large B cell lymphoma R R DLBCL

Site specific and latency associated second primary malignancy in follicular lymphoma survivors A SEER MP SIR study 2000 2022